NCT06444620 - B/F/TAF to DTG/3TC Switch Study | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

July 22, 2024

Primary Completion Date

December 22, 2025

Study Completion Date

December 22, 2026

Conditions

HIV-1-infection

Interventions

DRUG

DTG/3TC

This is a fixed-dose combined DTG/3TC pill each containing 50mg of dolutegravir and 300mg of lamivudine

Trial Locations (2)

Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu

Kenyatta National Hospital, Nairobi